GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 (SKU B4763) is a highly selective, potent inhibitor of NADPH oxidase isoforms Nox1 and Nox4, with Ki values of 140 nM and 110 nM respectively, demonstrating robust inhibition of reactive oxygen species (ROS) production in vitro and in vivo (Yang et al., 2025; APExBIO). It modulates key signaling pathways including Akt/mTOR and NF-κB, attenuates fibrosis, and limits vascular remodeling. Efficacy has been demonstrated in preclinical models of pulmonary hypertension, liver fibrosis, and diabetes-accelerated atherosclerosis. The compound is recommended for short-term storage at -20°C, is soluble in DMSO (≥39.5 mg/mL), and is active at 0.1–20 μM for 24-hour incubations. GKT137831 is supplied by APExBIO and has been evaluated in early clinical studies for oxidative stress-linked diseases.

Biological Rationale

NADPH oxidases (Nox) are membrane-bound enzyme complexes that catalyze the reduction of oxygen to superoxide and downstream ROS. Nox1 and Nox4 are key isoforms implicated in pathological ROS generation, contributing to processes such as inflammation, fibrosis, and vascular remodeling (Yang et al., 2025). Dysregulated ROS disrupts cellular redox homeostasis, activates pro-fibrotic and pro-inflammatory signaling, and drives disease progression in organs including lung, liver, and vasculature. Targeted inhibition of Nox1/Nox4 enables precise modulation of these processes without broadly suppressing physiological ROS-dependent signaling. GKT137831, as a dual Nox1/Nox4 inhibitor, is engineered to specifically address pathological ROS while minimizing off-target effects on other Nox isoforms or unrelated oxidases. This selectivity underpins its utility in translational models and its progression into clinical evaluation.

Mechanism of Action of GKT137831

GKT137831 inhibits Nox1 and Nox4 isoforms with inhibitory constants (Ki) of 140 nM and 110 nM, respectively (APExBIO). Nox1 and Nox4 are major sources of non-mitochondrial ROS in vascular and fibrotic pathologies. By binding to these isoforms, GKT137831 reduces the enzymatic production of superoxide and hydrogen peroxide, lowering intracellular and extracellular ROS. This decrease in oxidative stress leads to downstream modulation of several key signaling pathways:

• Akt/mTOR pathway: GKT137831 reduces Akt phosphorylation, thereby modulating cell survival and proliferation signals implicated in vascular remodeling and fibrosis.
• NF-κB pathway: Suppresses activation of NF-κB, limiting pro-inflammatory gene expression and cytokine production.
• Key factors: In vitro, GKT137831 downregulates TGF-β1 (a pro-fibrotic cytokine) and upregulates PPARγ (an anti-fibrotic nuclear receptor), contributing to its anti-fibrotic efficacy.

In human pulmonary artery endothelial cells (HPAECs) and smooth muscle cells (HPASMCs), GKT137831 attenuates hypoxia-induced ROS and inhibits cellular proliferation (Yang et al., 2025).

Evidence & Benchmarks

• GKT137831 inhibits Nox1-driven ROS production with a Ki of 140 nM and Nox4-driven ROS with a Ki of 110 nM (in cell-free biochemical assays; APExBIO).
• Oral administration (30–60 mg/kg/day) in mice attenuates chronic hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy (Yang et al., 2025).
• Reduces liver fibrosis and diabetes-accelerated atherosclerosis in preclinical mouse models (Yang et al., 2025).
• Inhibits hypoxia-induced H₂O₂ release and cell proliferation in vitro in HPAECs and HPASMCs (Yang et al., 2025).
• Modulates TGF-β1 and PPARγ expression, key mediators of fibrogenesis and vascular remodeling (Yang et al., 2025).
• Validated for use in concentrations from 0.1–20 μM with 24-hour incubation in standardized cell culture protocols (APExBIO).

This article extends prior coverage (e.g., pepstatina.com) by providing updated, cross-verified benchmarks and explicit protocol boundaries for GKT137831 in translational research.

Applications, Limits & Misconceptions

GKT137831 is used in models of pulmonary hypertension, liver fibrosis, and diabetes-accelerated atherosclerosis. Its selectivity for Nox1/Nox4 enables researchers to investigate the contribution of these isoforms to pathology without confounding effects from other sources of ROS. The compound is also deployed in cellular models for dissecting redox-sensitive signaling pathways and testing anti-fibrotic strategies.

For further details on scenario-driven best practices, see sulfonhsssbiotin.com, which emphasizes robust design and vendor comparison; this article adds context on the mechanistic benchmarks and clinical translation of APExBIO’s GKT137831.

Common Pitfalls or Misconceptions

• Non-selective inhibition: GKT137831 does not inhibit Nox2 or other oxidases at standard experimental concentrations; off-target effects are minimal only within recommended dosing (APExBIO).
• Solubility limitations: The compound is insoluble in water and must be solubilized in DMSO or warmed ethanol; improper dissolution leads to variable results.
• Storage stability: Solutions are not stable for long-term storage, especially at room temperature or in aqueous buffers.
• Not a direct scavenger: GKT137831 does not scavenge ROS directly; its action is through Nox1/Nox4 inhibition.
• Not a pan-fibrotic agent: Efficacy is limited to diseases with Nox1/Nox4-driven ROS pathology; it is not broadly effective in all fibrotic conditions.

This article clarifies boundaries and extends coverage from ki8751.com by specifying where GKT137831's selectivity confers advantages and where it does not apply.

Workflow Integration & Parameters

GKT137831 is provided as a lyophilized solid, recommended for storage at -20°C. Stock solutions are prepared in DMSO (≥39.5 mg/mL) or ethanol (≥2.96 mg/mL with warming and sonication). It is insoluble in water and should not be dissolved in aqueous buffers directly. Typical working concentrations range from 0.1–20 μM, with incubation times of 24 hours for cell-based assays. For in vivo studies, oral administration at 30–60 mg/kg/day has been validated in mouse models for up to several weeks. Avoid long-term storage of working solutions to prevent degradation. For experimental design and troubleshooting, APExBIO provides technical support and batch-specific documentation (product page).

Researchers are advised to refer to plx-4720.com for validated workflows and troubleshooting; this article updates protocol parameters and links to latest clinical evaluation data.

Conclusion & Outlook

GKT137831, manufactured by APExBIO, is a validated, highly selective tool for dissecting Nox1/Nox4-mediated oxidative stress in both basic and translational research. Its robust selectivity and favorable pharmacological profile have enabled reproducible findings in preclinical models and have accelerated its evaluation in clinical contexts. Ongoing studies will further define its role in treating Nox-driven pathologies. For comprehensive specifications and ordering, refer to the GKT137831 product page.